The Medicines Co. (MDCO)

36.39
0.61 1.60
NASDAQ : Health Technology
Prev Close 37.00
Open 37.01
Day Low/High 36.26 / 37.17
52 Wk Low/High 16.69 / 41.33
Volume 1.22M
Avg Volume 1.46M
Exchange NASDAQ
Shares Outstanding 79.28M
Market Cap 2.93B
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
The Medicines Company Advances Clinical Development Of Investigational First-in-Class PCSK9 Synthesis Inhibitor For Atherosclerotic Cardiovascular Disease (ASCVD)

The Medicines Company Advances Clinical Development Of Investigational First-in-Class PCSK9 Synthesis Inhibitor For Atherosclerotic Cardiovascular Disease (ASCVD)

The Medicines Company (NASDAQ:MDCO) today announced that it has initiated study sites and begun enrolling patients in the ORION-1 Phase 2 study to compare the effect of different doses of ALN-PCSsc given as subcutaneous...

Medicines (MDCO) Stock: Weak On High Volume Today

Medicines (MDCO) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Medicines (MDCO) as a weak on high relative volume candidate

The Medicines Company To Participate In J.P. Morgan 34th Annual Healthcare Conference

The Medicines Company To Participate In J.P. Morgan 34th Annual Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the J.

Today's Dead Cat Bounce Stock Is Medicines (MDCO)

Today's Dead Cat Bounce Stock Is Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a "dead cat bounce" (down big yesterday but up big today) candidate

The Medicines Company Agrees To Divest Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company Agrees To Divest Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company (NASDAQ:MDCO) today announced that it has entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company's global portfolio of three...

The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy

The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy

The Medicines Company (NASDAQ:MDCO) today announced that the European Heart Journal - Cardiovascular Pharmacotherapy has published results of its Phase 1 study for MDCO-216, a compound under development for the reduction...

Glenn Sblendorio To Retire As President And Chief Financial Officer From The Medicines Company

Glenn Sblendorio To Retire As President And Chief Financial Officer From The Medicines Company

The Medicines Company (NASDAQ:MDCO) announced today that Glenn Sblendorio, President and Chief Financial Officer, will retire from the company effective March 31, 2016.

The Medicines Company To Participate In Oppenheimer 26th Annual Healthcare Conference

The Medicines Company To Participate In Oppenheimer 26th Annual Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Oppenheimer 26th Annual Healthcare Conference in New York, NY on Wednesday, December 9 at 8:35 am EST.

The Medicines Company Receives European Commission Approval For IONSYS® 40 Micrograms Per Dose Transdermal System (fentanyl) To Treat Post-Operative Pain In Adult Hospitalized Patients

The Medicines Company Receives European Commission Approval For IONSYS® 40 Micrograms Per Dose Transdermal System (fentanyl) To Treat Post-Operative Pain In Adult Hospitalized Patients

The Medicines Company today announced that the European Commission has granted marketing authorization for IONSYS® (40 micrograms per dose transdermal system), with active ingredient fentanyl, for the management of...

Federal Circuit Overturns District Court Decision On Angiomax Patents; Grants The Medicines Company's Request For Rehearing Of Appeal

Federal Circuit Overturns District Court Decision On Angiomax Patents; Grants The Medicines Company's Request For Rehearing Of Appeal

The Medicines Company's petition for en banc review of the U.S.

Medicines Company (MDCO) Marked As A Barbarian At The Gate

Medicines Company (MDCO) Marked As A Barbarian At The Gate

Trade-Ideas LLC identified Medicines Company (MDCO) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen

Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and  The Medicines Company (Nasdaq:MDCO), a leading biopharmaceutical development and cardiovascular product company, today...

The Medicines Company To Present New Data On Cardiovascular Portfolio At American Heart Association (AHA) Scientific Sessions

The Medicines Company To Present New Data On Cardiovascular Portfolio At American Heart Association (AHA) Scientific Sessions

The Medicines Company today announced it will present new data from both its established antithrombotic portfolio and investigational hypercholesterolemia pipeline at the 2015 Scientific Sessions of the American Heart...

Medicines Company (MDCO) Flagged As Strong On High Volume

Medicines Company (MDCO) Flagged As Strong On High Volume

Trade-Ideas LLC identified Medicines Company (MDCO) as a strong on high relative volume candidate

The Medicines Company Reports Third-Quarter And First Nine Months 2015 Business And Financial Results

The Medicines Company Reports Third-Quarter And First Nine Months 2015 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the third quarter and the nine months ended September 30, 2015.

Results Of First-in-Man Study With Investigational Anesthetic ABP-700 Presented At ANESTHESIOLOGY® 2015 And International Society Of Anesthetic Pharmacology Annual Meetings

Results Of First-in-Man Study With Investigational Anesthetic ABP-700 Presented At ANESTHESIOLOGY® 2015 And International Society Of Anesthetic Pharmacology Annual Meetings

Results of the first-in-man study, ANVN-01, with ABP-700, a positive allosteric GABA A receptor modulator in development for general anesthesia and procedural sedation, were presented at the annual meetings of...

The Medicines Company To Present Data On Potentially Innovative Surgical Anesthetic At American Society Of Anesthesiologists 2015 Meeting

The Medicines Company To Present Data On Potentially Innovative Surgical Anesthetic At American Society Of Anesthesiologists 2015 Meeting

The Medicines Company will present new clinical data on ABP-700 - a novel intravenous (IV) anesthetic under development for general anesthesia and procedural sedation - at ANESTHESIOLOGY 2015, the annual congress of the...

The Medicines Company To Announce Third Quarter 2015 Financial Results On Tuesday, November 3, 2015

The Medicines Company To Announce Third Quarter 2015 Financial Results On Tuesday, November 3, 2015

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Tuesday, November 3 at 8:30 a.

The Medicines Company Announces Participation At IDWeek 2015 Meeting

The Medicines Company Announces Participation At IDWeek 2015 Meeting

The Medicines Company today announced that it will make four presentations on its infectious disease programs at IDWeek between October 7 - 11 in San Diego, CA.

The Medicines Company Announces BARDA Exercises Next Option On Contract For Support Of The Development Of CARBAVANCE® (meropenem/RPX7009) For Drug-Resistant Gram-Negative Pathogens

The Medicines Company Announces BARDA Exercises Next Option On Contract For Support Of The Development Of CARBAVANCE® (meropenem/RPX7009) For Drug-Resistant Gram-Negative Pathogens

The Medicines Company (NASDAQ:MDCO) today announced that Rempex Pharmaceuticals, a wholly owned subsidiary, has been awarded the next option on a contract by the Biomedical Advanced Research and Development Authority...

10 Best Nasdaq Biotech Stocks in the Third Quarter

10 Best Nasdaq Biotech Stocks in the Third Quarter

Here are the 10 stocks in the biotech sector which had the best third-quarter.

Short Interest Makes 17.2% Move For MDCO

Short Interest Makes 17.2% Move For MDCO

The most recent short interest data has been released by the NASDAQ for the 09/15/2015 settlement date, which shows a 2,185,141 share increase in total short interest for Medicines Co , to 14,884,599, an increase of 17.21% since 08/31/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week Of November 20th Options Trading For Medicines

First Week Of November 20th Options Trading For Medicines

Investors in Medicines Co saw new options begin trading this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDCO options chain for the new November 20th contracts and identified one put and one call contract of particular interest.

The Medicines Company Receives CHMP Positive Opinion For IONSYS® To Treat Post-operative Pain In Adult Patients

The Medicines Company Receives CHMP Positive Opinion For IONSYS® To Treat Post-operative Pain In Adult Patients

The Medicines Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorization for IONSYS® (40...

Trade-Ideas: Medicines Company (MDCO) Is Today's Post-Market Leader Stock

Trade-Ideas: Medicines Company (MDCO) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Medicines Company (MDCO) as a post-market leader candidate

The Medicines Company Reports Discovery Of New Series Of Beta-Lactamase Inhibitors At ICAAC/ICC 2015

The Medicines Company Reports Discovery Of New Series Of Beta-Lactamase Inhibitors At ICAAC/ICC 2015

Researchers at The Medicines Company presented data today on a new series of Beta-Lactamase Inhibitors (BLIs) at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of...

New Treatment Options For Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Needed, According To Study By The Medicines Company

New Treatment Options For Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Needed, According To Study By The Medicines Company

Researchers at The Medicines Company presented data from a multi-national cohort that demonstrates the mortality and morbidity, and poor outcomes, associated with current therapies in patients with infections due to...

The Medicines Company Announces Participation At ICAAC/ICC 2015 Meeting

The Medicines Company Announces Participation At ICAAC/ICC 2015 Meeting

The Medicines Company (NASDAQ:MDCO) today announced that 18 presentations on its infectious disease programs will be presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the...

Medicines Company (MDCO) Hits New Lifetime High Today

Medicines Company (MDCO) Hits New Lifetime High Today

Trade-Ideas LLC identified Medicines Company (MDCO) as a new lifetime high candidate